SAN ANTONIO — In the course of caring for individuals with psoriasis, clinicians should have patients complete the validated ...

Q3 2025 Earnings Call Transcript November 6, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.67, ...

Discover Viatris' Q3 2025 earnings highlights: strengthened financials, raised guidance, pipeline progress, and strategic cost savings.

Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...

Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - ...

Viatris, Inc. (($VTRS)) has held its Q3 earnings call. Read on for the main highlights of the call. Viatris, Inc. recently held its earnings call, ...

Ascendis Pharma A/S v. Biomarin Pharm. Inc., 25-5696 (N.D. Cal.) July 7, 2025 Hon. P. Casey Pitts Voxzogo® (vosoritide powder for injection) RE48,267 Janssen Pharms ...

Replay the call for the latest insights. Chart does not reflect overnight price.

Tune into live earnings calls Now streaming directly on quote pages. Chart does not reflect overnight price.

Analgesia for dehorning calves has been a somewhat controversial subject since I can remember. We learned in vet school about lidocaine infiltration with needles including nerve blocks and/or whether ...